Next Science Ltd (ASX: NXS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Next Science Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$42.43 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
292.63 million
Earnings per share
-0.032
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Next Science Ltd (ASX: NXS)
Latest News
Share Fallers
Here's why the Next Science (ASX:NXS) share price is sinking 6% lower
Share Market News
Next Science (ASX:NXS) share price higher on earnings mixed bag
Share Market News
The Next Science (ASX:NXS) share price is up 8% today. Here's why
Share Gainers
Why City Chic, Kogan, Next Science, & NIB shares are charging higher
Share Market News
Why the Next Science (ASX:NXS) share price is 5% higher today
Share Market News
Why the Next Science (ASX:NXS) share price dropped 9% today
Share Market News
Why the Next Science (ASX:NXS) share price is falling today
Share Market News
Why the Next Science share price is dropping lower
Capital Raising
Why the Next Science (ASX:NXS) share price is on watch
Share Gainers
Why Alcidion, Bubs, IGO, & Next Science shares are pushing higher
Share Gainers
Next Science share price surges higher on TGA approval
Share Fallers
Why Caltex, Next Science, Northern Star, & Sydney Airport are tumbling lower
NXS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Next Science Ltd
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
NXS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 31 Dec 2025 | $0.15 | $0.00 | 0.00% | 4,327,073 | $0.14 | $0.15 | $0.14 |
| 30 Dec 2025 | $0.14 | $0.00 | 0.00% | 15,171 | $0.14 | $0.14 | $0.14 |
| 29 Dec 2025 | $0.14 | $0.00 | 0.00% | 298,057 | $0.15 | $0.15 | $0.14 |
| 24 Dec 2025 | $0.15 | $-0.01 | -6.67% | 8,986,423 | $0.15 | $0.15 | $0.15 |
| 23 Dec 2025 | $0.15 | $0.01 | 7.41% | 1,813,896 | $0.14 | $0.15 | $0.14 |
| 22 Dec 2025 | $0.14 | $-0.01 | -7.14% | 358,121 | $0.14 | $0.14 | $0.14 |
| 19 Dec 2025 | $0.14 | $0.01 | 7.41% | 372 | $0.14 | $0.14 | $0.14 |
| 18 Dec 2025 | $0.14 | $0.00 | 0.00% | 8,944 | $0.14 | $0.14 | $0.14 |
| 17 Dec 2025 | $0.14 | $0.00 | 0.00% | 13,241 | $0.14 | $0.14 | $0.14 |
| 16 Dec 2025 | $0.14 | $-0.01 | -7.14% | 8,750 | $0.14 | $0.14 | $0.14 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 14 Jul 2025 | Harry Hall(IV) | Exercise | 465,131 | $65,118 |
Conversion of securities. 22,79,525 Rights
|
| 14 Jul 2025 | Harry Hall(IV) | Issued | 465,131 | $65,118 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Grant Hummel | Non-Executive Director | Aug 2023 |
Mr Hummel has been a partner of an Australian law firm for over fifteen years. Grant has experience with corporate and commercial transactions, with expertise in advising primary care, allied health, medical device and life science clients. He is the Chair of People and Culture Committee.
|
| Ms Aileen Stockburger | Non-Executive DirectorNon-Executive Chairman | Oct 2018 |
Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Aileen led Johnson & Johnson's efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson's largest medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in other M&A transactions including Pfizer Consumer Healthcare (US$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. She is a Member of the Risk, People & Culture Committee.
|
| Ms Katherine (Kathy) Ostin | Non-Executive Director | Oct 2023 |
Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in aged care and healthcare sectors, having led KPMG's New South Wales Health, Ageing and Human Services audit practice from 2006 to 2017. During her 24 years with KPMG, Kathy worked in Australia, the U.S., Asia, and the UK. She is Chair of the Risk Committee.
|
| Ms Gillian Maria Nairn | Company Secretary | Jun 2018 |
-
|
| Gillian Maria Nairn | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 58,460,457 | 20.01% |
| Auckland Trust Company Ltd <Second Pacific Master Superannuation Fund> | 56,019,938 | 19.17% |
| UBS Nominees Pty Ltd | 20,054,081 | 6.86% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 6,694,440 | 2.29% |
| Mr Charles Robert Dirck Wittenoom | 5,571,349 | 1.91% |
| S G Andrew Pty Ltd <S G Andrew Super Fund A/C> | 4,940,000 | 1.69% |
| Mr James Willis Mozley Jr | 4,676,732 | 1.60% |
| Citicorp Nominees Pty Limited | 4,671,979 | 1.60% |
| Mr James Fong Seeto | 4,600,000 | 1.57% |
| Dr Matthew Franco Myntti | 4,171,824 | 1.43% |
| J P Morgan Nominees Australia Pty Limited | 3,349,443 | 1.15% |
| Mr Dean Anthony Mackenzie | 3,187,175 | 1.09% |
| Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> | 2,921,187 | 1.00% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 2,852,962 | 0.98% |
| Bond Street Custodians Limited <Lam1 D08047 A/C> | 2,460,427 | 0.84% |
| Twenty Fifth Elporto Pty Ltd <Twenty Fifth Elporto Sf A/C> | 2,300,000 | 0.79% |
| Judith Lee Mitchell | 2,284,503 | 0.78% |
| Mrs Gwendoline Louise King & Mr Simon George Andrew | 2,000,000 | 0.68% |
| Belgravia Strategic Equities Pty Ltd | 1,965,000 | 0.17% |
| Mr Richard Hugo Hamersley <Greenidge A/C> | 1,947,596 | 0.65% |
